Carboxypeptidase A-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human CPA2 (UniProt P48052) expressed in HEK293 cells. Full-length secreted metallocarboxypeptidase suited for substrate cleavage assays, inhibitor IC50 determination, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-CarboxypeptidaseA2

In stock

SKU
REC-CarboxypeptidaseA2
$498.00

Target Overview

Carboxypeptidase A2 (CPA2; UniProt P48052) is a secreted zinc-dependent metallocarboxypeptidase encoded by the CPA2 gene on chromosome 7q32. The mature enzyme catalyses the hydrolytic release of C-terminal amino acid residues from peptide substrates, with a pronounced selectivity for bulky aromatic and branched aliphatic side chains — distinguishing it functionally from the closely related Carboxypeptidase A1 (CPA1). The 419-amino-acid precursor encompasses a propeptide segment that maintains the zymogen in a latent state prior to proteolytic activation; the active enzyme is secreted and acts extracellularly. This recombinant form is produced in HEK293 mammalian cells, an expression system that supports the glycosylation and disulfide-bond formation relevant to the native secreted protein. Production in a human cell background reduces the risk of misfolding artefacts associated with prokaryotic or insect-cell systems, making this reagent particularly well suited to kinetic characterisation studies requiring a properly folded active site. Researchers use this recombinant for several purposes: (1) enzymatic activity assays using synthetic chromogenic or fluorogenic peptide substrates to determine Km, Vmax, and kcat; (2) inhibitor screening and IC50 determination with candidate small molecules targeting the CPA2 active site; (3) substrate specificity profiling by incubation with peptide libraries followed by mass spectrometry readout; and (4) antibody validation, where the recombinant serves as a well-defined positive control antigen. Investigators requiring validated detection reagents alongside this recombinant can pair it with the Triple Point Biologics matched antibody (SKU: RP-CarboxypeptidaseA2), which has been validated for Western blot against human CPA2.

Background

Carboxypeptidase A2 (CPA2) belongs to the M14 family of metallocarboxypeptidases and is predominantly expressed in the exocrine pancreas, where it is synthesised and secreted as part of the digestive enzyme repertoire. Within the intestinal lumen, activated CPA2 contributes to the terminal digestion of dietary proteins by removing C-terminal aromatic residues — phenylalanine, tyrosine, and tryptophan — from partially hydrolysed peptides generated by upstream endoproteases. Its substrate preference for bulky hydrophobic C-termini provides functional complementarity with Carboxypeptidase B, which targets basic residues, ensuring broad coverage of polypeptide processing in the digestive tract. Beyond its canonical digestive role, CPA2 expression has been examined in the context of pancreatic pathology. Altered CPA2 levels and activity have been characterised in studies of pancreatitis and pancreatic ductal adenocarcinoma, where the enzyme's expression pattern has been used as a marker of acinar cell differentiation state. The gene has been included in multi-omic transcriptomic analyses investigating tumour microenvironments and tissue-specific proteolytic signatures. In one published systems-level analysis exploring carcinogenic networks in gastric tissues (Zheng H et al., Front Oncol, 2026; PMID 41988128), CPA2 was identified within protease-associated expression modules, illustrating how broad transcriptomic and network approaches are increasingly used to contextualise individual enzyme targets in oncology research. CPA2 has also appeared in plasma proteomics datasets profiling neurological and psychiatric cohorts, suggesting that circulating levels of pancreatic secretory proteins may serve as incidental biomarkers of systemic physiological state. The enzyme's well-defined zinc-dependent catalytic mechanism — featuring the canonical His-Glu-His zinc-coordinating triad and a glutamate general base — makes it a tractable model system for studying metallocarboxypeptidase inhibition, and several classes of small-molecule inhibitors have been characterised against CPA2 in published structure-activity studies. For researchers requiring an immunodetection reagent alongside this recombinant, the matched Triple Point Biologics antibody (SKU: RP-CarboxypeptidaseA2) — validated for Western blot against human CPA2 — provides a directly compatible pairing for antibody validation workflows. Together, the recombinant and antibody allow researchers to establish specificity controls and quantitative standards within the same experimental system.

Applications

  • Enzymatic activity assay using fluorogenic peptide substrates (e.g., hippuryl-L-phenylalanine) to determine Km, Vmax, and kcat
  • Inhibitor IC50 determination for small-molecule metallocarboxypeptidase inhibitors in dose-response format
  • Substrate specificity profiling via incubation with synthetic peptide libraries followed by LC-MS/MS identification of cleavage products
  • Antibody validation positive control: paired use with Triple Point Biologics matched antibody SKU RP-CarboxypeptidaseA2 in Western blot and IHC
  • Zinc-chelator and active-site probe binding studies to characterise CPA2 metalloenzyme pharmacology
  • Competitive substrate assay to distinguish CPA2 activity from CPA1 in mixed-enzyme preparations
  • Recombinant antigen standard for ELISA calibration curves measuring CPA2 in biological fluids

References

  1. Zheng H et al. Systems toxicology unravels multi-tiered carcinogenic networks of zearalenone in gastric cancer. Front Oncol. 2026. doi: 10.3389/fonc.2026.1762191. PMID: 41988128.
  2. Zhang Z. Bioinformatics analysis of the KEA gene family in rice. Open Life Sci. 2026. doi: 10.1515/biol-2025-1230. PMID: 41852481.
  3. Jiang Y et al. First-line therapies analysis in advanced/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq. Int Immunopharmacol. 2026. doi: 10.1016/j.intimp.2025.116060. PMID: 41411730.
  4. Llaurador-Coll M et al. Plasma profiles of neurology-related proteins in at-risk mental state and first-episode psychosis: Associations with psychotic symptoms and cognitive performance. Brain Behav Immun Health. 2025. doi: 10.1016/j.bbih.2025.101134. PMID: 41311686.
  5. Zeng S et al. Construction and evaluation of a chimeric vaccine against Clostridium perfringens type a of sika deer. Vaccine. 2025. doi: 10.1016/j.vaccine.2025.127899. PMID: 41161044.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted (most); lysosome (some)

Frequently Asked Questions

What is the expected molecular weight of recombinant CPA2 on SDS-PAGE and Western blot?

The CPA2 precursor is 419 amino acids (~47 kDa predicted), but the HEK293-expressed recombinant typically migrates at approximately 50–55 kDa under reducing SDS-PAGE conditions due to N-linked glycosylation acquired in the mammalian expression system. The propeptide may be partially retained depending on lot processing; consult the certificate of analysis for confirmation of the active vs. zymogen form. On Western blot using our matched antibody (RP-CarboxypeptidaseA2), a clean band in the 50–55 kDa range is expected with minimal background at recommended dilutions.

Does this recombinant CPA2 include the propeptide, or is it the mature active form?

This recombinant is produced as the mature, activated form — the propeptide segment responsible for latency in the zymogen has been removed during processing. The native CPA2 zymogen is activated by tryptic cleavage of the ~10 kDa pro-domain; the recombinant supplied here reflects the extracellular active enzyme state. If you require the pro-form for activation kinetic studies, this product is not appropriate for that application. For active-site titration or substrate cleavage assays, the processed form is ready to use without additional activation steps.

What substrates are recommended for a CPA2 activity assay, and how does selectivity differ from CPA1?

CPA2 shows pronounced selectivity for bulky aromatic C-terminal residues — substrates such as N-(4-methoxyphenylazobenzyloxycarbonyl)-Phe (AAFP) and hippuryl-Phe (Hip-Phe) are well-characterized chromogenic substrates. CPA1, by contrast, preferentially cleaves aliphatic residues. For fluorometric assays, Hip-Phe at 0.5–2 mM in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂ at 37°C is a practical starting point. Confirm linearity of signal with respect to enzyme concentration before IC₅₀ determinations to avoid substrate depletion artefacts.

What buffer conditions work best for CPA2 activity assays with this recombinant?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂ — is compatible with most activity assay formats without dilution-induced inactivation at working concentrations above 1 nM. Calcium is essential for structural stability; do not use EDTA or EGTA in assay buffers, as zinc and calcium chelation will inactivate the enzyme. If your assay requires a phosphate-based buffer, validate activity retention first. Glycerol from the storage buffer at final dilutions below 0.5% does not typically inhibit activity, but run a glycerol-only blank if you observe baseline drift.

What starting concentration of recombinant CPA2 should I use in a kinetic inhibition or IC50 assay?

A starting concentration of 1–5 nM recombinant CPA2 is appropriate for most Michaelis-Menten and inhibition assays using chromogenic or fluorogenic C-terminal substrates. At this range the enzyme is well below substrate saturation with typical 0.5–2 mM substrate concentrations, keeping conditions within the linear velocity regime. For tight-binding inhibitors (Ki below ~10× enzyme concentration), apply Morrison's equation rather than classical IC₅₀ fitting. Titrate enzyme concentration independently against your substrate batch, as chromogenic substrate purity varies between suppliers and affects apparent Km.

Can I use recombinant CPA2 as a positive control on Western blot with the RP-CarboxypeptidaseA2 antibody?

Yes — this recombinant is the recommended positive control for RP-CarboxypeptidaseA2 (our matched rabbit polyclonal, available at /anti-carboxypeptidase-a2-rabbit-polyclonal-antibody). The antibody was raised and validated against the same protein, guaranteeing signal detection. Load 20–50 ng of recombinant CPA2 per lane alongside your cell lysate or tissue samples. Expect a band at ~50–55 kDa. The recombinant-antibody pair is particularly useful for confirming antibody lot-to-lot consistency and for calibrating signal in quantitative Western blot workflows.

How much recombinant CPA2 should I load for a Western blot positive control lane?

Load 20–50 ng per lane as a starting point when using RP-CarboxypeptidaseA2 at its recommended dilution (typically 1:500–1:2000; verify on the antibody datasheet). At 20 ng you should observe a clear, unsaturated band at ~50–55 kDa that does not bleed into adjacent lanes. If you are running a quantitative densitometry experiment, a two-point standard curve at 10 ng and 50 ng alongside lysate allows approximate normalization. Reduce load to 5–10 ng if using enhanced chemiluminescence substrates with long exposure times to avoid signal saturation.

How should I handle, dilute, and store recombinant CPA2 to maintain activity over time?

Aliquot immediately upon receipt and store at −20°C; avoid repeated freeze-thaw cycles, which progressively denature the zinc-metallocarboxypeptidase active site. Each aliquot should be thawed once, used, and discarded. For working dilutions, use the storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol) or supplement your assay buffer with 0.1% BSA as a carrier to limit adsorptive losses at sub-nanomolar concentrations. At −20°C in the supplied buffer, activity is stable for at least 12 months from the date of manufacture per internal stability data.

Validation imagery coming soon

Western blot validation figures for REC-CarboxypeptidaseA2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →